Munich, Bavaria, Germany
I am dedicated to improving patient outcomes at the intersection of science, innovation, and business. I have experience in immunology, hematology, cardiology, pulmonology, neurology, and dermatology, particularly in launching and supporting various assets in specialty care and rare diseases, which I have gained through my various medical and marketing roles. I am committed to advancing healthcare in the long term, driven by a passion for patients and science. I welcome opportunities to connect with like-minded professionals. Disclaimer: All opinions expressed are my own and do not represent the position of my former or current employers.
Leading a team of high-performing Medical Science Liaisons, driving scientific exchange and medical innovation across atopic dermatitis, prurigo nodularis, chronic spontaneous urticaria, and emerging dupilumab pipeline indications.
Shaping the IL-5 medical narrative across respiratory and rare disease indications and preparing the launch of depemokimab in chronic rhinosinusitis with nasal polyps.
Assignment: Representing the EUCAN & International region within the global amyloidosis franchise.
Medical launch lead for anselamimab/CAEL-101 in light chain amyloidosis in Germany. Medical oversight over the clinical stage of ALXN2220/NI006 in transthyretin amyloidosis. Medical management for the amyloidosis portfolio. (04/2023-09/2024) Medical launch lead for ravulizumab (ULTOMIRIS) in generalized myasthenia gravis (gMG) and responsibility for the HTA process in Germany. Lifecycle management for eculizumab (SOLIRIS) in gMG and neuromyelitis optica spectrum disorder. Pipeline responsibility. (05/2022-06/2023) Additional responsibilities: Developed a roadmap with our CFO for an Alexion/AstraZeneca Diagnostics Innovation & Health Equity Hub.
Field-based Medical Affairs for dupilumab (DUPIXENT) in immunology/dermatology (atopic dermatitis, prurigo nodularis, chronic spontaneous urticaria)
Development program 1st assignment: Medical management for dupilumab (DUPIXENT) in immunology/dermatology (atopic dermatitis) 2nd assignment: Brand management for LIBTAYO (cemiplimab) in immuno-oncology/non-melanoma skin cancer (CSCC and BCC)
MBA internship and freelance consultant